A meta-analysis of implant-based breast reconstruction and timing of adjuvant radiation therapy.
Joseph A Ricci, Sherise Epstein, Adeyiza O Momoh...
https://pubmed.ncbi.nlm.nih.gov/28985836/Actively Recruiting
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2026-04-13
250
Participants Needed
9
Research Sites
104 weeks
Total Duration
This research aims to evaluate the NovaGray RILA Breast4 tests ability to predict side effects linked to radiotherapy and the impact of immediate implant breast reconstruction in patients with breast cancer. The study focuses on women undergoing mastectomy followed by radiotherapy, which can cause side effects affecting cosmetic outcomes and quality of life. The test measures lymphocyte T-CD8 apoptosis to assess individual risk of severe radiation-induced breast fibrosis, potentially enabling personalized treatment planning. The study involves performing the NovaGray RILA Breast4 test using blood samples taken between 30 days before and the first day of radiotherapy, and again 12 months after radiotherapy ends. For patients receiving chemotherapy, the test is also done before the first chemotherapy injection, whether neoadjuvant or adjuvant. The intervention is a device-based test aimed at predicting radiosensitivity related to breast reconstruction and radiotherapy. Participants will have blood drawn for the test at specified times before and after treatments. Researchers will assess the tests ability to predict capsular contracture 12 months after radiotherapy, along with other outcomes such as cosmetic and functional results, patient satisfaction, and quality of life over a 24-month period. Follow-up includes monitoring surgical success, biological and tumor factors, and test stability after chemotherapy to understand the tests precision and clinical utility.
CONDITIONS
Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
A
Aurore MOUSSION
E
Emmanuelle TEXIER
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institut du Cancer de Montpellier - Val d'Aurelle
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From 30 days before to the first day of radiotherapy or chemotherapy
Participants have the NovaGray RILA Breast® test performed, which involves blood sampling to evaluate radiosensitivity before radiotherapy and chemotherapy when applicable.
1 to 2 visits depending on treatment schedule
Duration - Up to 24 months post treatment
Participants undergo follow-up testing and assessments to monitor capsular contracture, cosmetic and functional outcomes, quality of life, and the stability of the radiosensitivity test up to 24 months after treatment.
Visits at 6, 12, 18, and 24 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Joseph A Ricci, Sherise Epstein, Adeyiza O Momoh...
https://pubmed.ncbi.nlm.nih.gov/28985836/Sally K Ng, Rowena M Hare, Ronny J Kuang...
https://pubmed.ncbi.nlm.nih.gov/25003439/Benjamin H L Howes, David I Watson, Chris Xu...
https://pubmed.ncbi.nlm.nih.gov/27406255/M Barry, M R Kell
https://pubmed.ncbi.nlm.nih.gov/21336948/G Nègre, T Balcaen, S Dast...
https://pubmed.ncbi.nlm.nih.gov/31383624/Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
https://pubmed.ncbi.nlm.nih.gov/15894097/Institut du Cancer de Montpellier - Val d'Aurelle
Lead Sponsor